Pfizer Sings Lyrica's Praises In Beating Earnings Guidance
Company beats recent lowered earnings guidance as a result of strong performance in its human health division as well as faster-than-anticipated cost savings from restructuring program.
Company beats recent lowered earnings guidance as a result of strong performance in its human health division as well as faster-than-anticipated cost savings from restructuring program.